Wealthsource Partners LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 8.1% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,128 shares of the biopharmaceutical company’s stock after selling 2,052 shares during the quarter. Wealthsource Partners LLC’s holdings in Pfizer were worth $777,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $103,000. D. Scott Neal Inc. raised its position in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $121,000. Finally, Herndon Capital Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $120,000. Institutional investors and hedge funds own 69.89% of the company’s stock.

Shares of Pfizer Inc. (NYSE PFE) traded up $0.37 during trading hours on Wednesday, reaching $36.58. 22,485,900 shares of the company traded hands, compared to its average volume of 19,926,613. The company has a market cap of $215,837.20, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 2.56 and a beta of 1.01. Pfizer Inc. has a one year low of $30.90 and a one year high of $36.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.50%. Pfizer’s payout ratio is 79.01%.

Several analysts have recently issued reports on PFE shares. BMO Capital Markets restated a “buy” rating and set a $39.00 target price on shares of Pfizer in a research report on Friday, November 10th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price on the stock in a research report on Thursday, November 23rd. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Tuesday, October 3rd. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Thursday, November 16th. Finally, UBS set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $38.77.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Wealthsource Partners LLC Has $777,000 Position in Pfizer Inc. (PFE)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/13/wealthsource-partners-llc-has-777000-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.